News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
796,599 Results
Type
Article (74504)
Company Profile (621)
Press Release (721474)
Section
Business (226934)
Career Advice (3735)
Deals (39092)
Drug Delivery (105)
Drug Development (88654)
Employer Resources (192)
FDA (17590)
Job Trends (17026)
News (385926)
Policy (38631)
Tag
Academia (2972)
Africa (1190)
Alliances (55594)
Alzheimer's disease (1233)
Approvals (17526)
Arizona (183)
Artificial intelligence (79)
Asia (47294)
Australia (8118)
Bankruptcy (389)
Best Places to Work (12182)
Biosimilars (68)
Biotechnology (433)
C2C Services and Suppliers (92252)
California (1670)
Canada (845)
Cancer (369)
Career advice (3176)
Cell therapy (118)
China (117)
Clinical research (68852)
Collaboration (120)
Colorado (71)
Connecticut (69)
COVID-19 (2738)
Cystic fibrosis (76)
Data (128)
Diabetes (71)
Diagnostics (6467)
Drug pricing (79)
Earnings (90936)
Employer resources (160)
Europe (107203)
Events (123504)
Executive appointments (95)
FDA (17762)
Florida (215)
Funding (99)
Gene therapy (88)
GLP-1 (599)
Government (4968)
Healthcare (20597)
Hotbed/Location (526157)
Illinois (288)
Indiana (147)
Infectious disease (2765)
Inflammatory bowel disease (98)
Interviews (733)
IPO (17351)
Job creations (4959)
Job search strategy (2614)
Kansas (98)
Layoffs (458)
Legal (9818)
Lung cancer (83)
Manufacturing (86)
Maryland (376)
Massachusetts (1477)
Medical device (14229)
Medtech (14232)
Mergers & acquisitions (21513)
Metabolic disorders (257)
Michigan (126)
Minnesota (222)
Neuroscience (1358)
New Jersey (506)
New York (506)
NextGen Class of 2024 (7594)
Non-profit (5048)
North Carolina (668)
Northern California (714)
Obesity (159)
Ohio (102)
Opinion (229)
Patents (63)
Pennsylvania (529)
People (62423)
Pharmaceutical (118)
Phase I (21153)
Phase II (30020)
Phase III (22709)
Pipeline (93)
Podcasts (72)
Postmarket research (3259)
Preclinical (9406)
Press Release (72)
Rare diseases (123)
Real estate (7125)
Recruiting (72)
Regulatory (24809)
Research institute (2629)
Resumes & cover letters (584)
South America (1559)
Southern California (641)
Startups (4169)
Texas (205)
United States (8078)
Vaccines (537)
Washington State (261)
Weight loss (152)
Date
Last 7 days (495)
Last 30 days (2305)
Last 365 days (40233)
2024 (26406)
2023 (42566)
2022 (53928)
2021 (58725)
2020 (57670)
2019 (51320)
2018 (39100)
2017 (36859)
2016 (37795)
2015 (43821)
2014 (38556)
2013 (34693)
2012 (36543)
2011 (36597)
2010 (36130)
796,599 Results for "merck and co".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Infectious Disease
CDC Backs Merck’s Capvaxive, Tees Up Pneumococcal Competition With Pfizer
In a potential challenge to Pfizer’s Prevnar 20, Merck’s Capvaxive has been recommended by the Centers for Disease Control and Protection for use in preventing invasive pneumococcal disease in adults.
July 1, 2024
·
2 min read
·
Tristan Manalac
Policy
CDC Backs Merck’s Capvaxive, Tees Up Pneumococcal Competition With Pfizer
In a potential challenge to Pfizer’s Prevnar 20, Merck’s Capvaxive has been recommended by the Centers for Disease Control and Protection for use in preventing invasive pneumococcal disease in adults.
July 1, 2024
·
2 min read
·
Tristan Manalac
Business
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Merck and Orion Corporation (“Orion”) today announced that notice has been provided of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor, and other candidates targeting CYP11A1 into an exclusive global license for Merck.
July 1, 2024
·
8 min read
Pharm Country
CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults
Merck, known as MSD outside of the United States and Canada, announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices unanimously voted to recommend CAPVAXIVE™ as an option for adults 65 years of age and older for pneumococcal vaccination.
June 27, 2024
·
6 min read
Business
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
Merck, known as MSD outside of the United States and Canada, will hold its second-quarter 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 30.
July 1, 2024
·
3 min read
N-Power Medicine Collaborates with Merck to Expand Oncologist and Patient Access to Clinical Trials
N-Power Medicine, a company reinventing the clinical trial process, is collaborating with Merck, known as MSD outside the United States and Canada, to enable a greater number of oncologists, and the patients they care for, to participate in clinical research.
July 1, 2024
·
2 min read
Deals
Merck to Acquire EyeBio
Merck, known as MSD outside of the United States and Canada, and Eyebiotech Limited, a privately held ophthalmology-focused biotechnology company, announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.
May 29, 2024
·
9 min read
Pharm Country
Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Merck, known as MSD outside of the United States and Canada, announced that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, at 10:00 a.m. EDT.
June 5, 2024
·
3 min read
Deals
Daiichi Pays Merck $170M for T-Cell Engager, Expands ADC Partnership
After dropping $4 billion on a deal with the Japanese company last year, Merck is getting back some of its investment as Daiichi Sankyo buys into a Phase I/II T-cell engager therapy acquired from Harpoon Therapeutics.
August 6, 2024
·
1 min read
·
Kate Goodwin
FDA
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
June 17, 2024
·
79 min read
1 of 79,660
Next